The Rainwater Foundation is proud to announce that the Tau Consortium has just launched a new matching grant program with The Alzheimer’s Association. It’s called the Tau Pipeline Enabling Program (T-PEP), and its goals is to accelerate the discovery of potential new therapies for tauopathies, including Alzheimer’s (AD), Frontotemporal Dementia (FTD), and Progressive Supranuclear Palsy (PSP). The intent of this program is to enrich the pipeline for therapy development by facilitating the translation of ideas into practical application.
Proposals responding to this program must target one or more steps in the drug discovery pipeline, including but not limited to i) assay development and high throughput screening, ii) lead optimization, and iii) IND-enabling studies, including related GMP scale-up/manufacture. Experimental drug compounds may be directed against the toxicity of tau directly and/or they may target mechanisms that promote or synergize tau formation or toxicity. Applications addressing related mechanisms must include the rationale that it will prevent, reduce, remove or otherwise mitigate the toxic effects of tau build up.
Both non-profit researchers and small for-profit companies are eligible to apply. The Principal Investigator of the project must be a full- time faculty member or paid employee of the organization submitting the proposal. Applications from post-doctoral researchers will not be accepted. For questions about eligibility, please contact the Alzheimer’s Association at email@example.com.
Full program details can be found at alz.org/T-PEP.
Letters of Intent (LOI) must be received by 5:00 PM ET, January 5, 2018.
All LOIs must be completed online at https://proposalcentral.altum.com. Only LOIs that meet program specific guidelines will be invited to submit full applications.